PDB25 COST-EFFECTIVENES OF REAL-WORLD USE OF GLP-1 RECEPTOR AGONISTS VERSUS OTHER GLUCOSE-LOWERING AGENTS IN TYPE 2 DIABETES

Abstract

Authors

C.Y. Yang Y.R. Chen C. Yang S. Kuo H.T. Ou

Full Text Cite This Article
Back to Volume 23, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×